Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human SPRY1 Antibodies:
anti-Rat (Rattus) SPRY1 Antibodies:
anti-Mouse (Murine) SPRY1 Antibodies:
Go to our pre-filtered search.
Human Monoclonal SPRY1 Primary Antibody for IHC (p), ELISA - ABIN564437
Moghaddam, Amini, Wei, Pourgholami, Morris: Initial report on differential expression of sprouty proteins 1 and 2 in human epithelial ovarian cancer cell lines. in Journal of oncology 2012
Show all 2 Pubmed References
Human Polyclonal SPRY1 Primary Antibody for ELISA, WB - ABIN564436
Mekkawy, De Bock, Lin, Morris, Wang, Pourgholami: Novel protein interactors of urokinase-type plasminogen activator receptor. in Biochemical and biophysical research communications 2010
Human Polyclonal SPRY1 Primary Antibody for ELISA, IHC - ABIN4355747
Hanafusa, Torii, Yasunaga, Matsumoto, Nishida: Shp2, an SH2-containing protein-tyrosine phosphatase, positively regulates receptor tyrosine kinase signaling by dephosphorylating and inactivating the inhibitor Sprouty. in The Journal of biological chemistry 2004
Although the expression of SPRY1 was low when compared with other tumors, SPRY1 was variably expressed in primary Ewing sarcoma tumors and higher expression levels were significantly associated with improved outcome in a large patient cohort.
SPRY1 and SPRY2 (show SPRY2 Antibodies) mRNA transcripts were significantly upregulated in human CRC (show CALR Antibodies). Suppression of SPRY2 (show SPRY2 Antibodies) repressed AKT2 (show AKT2 Antibodies) and EMT (show ITK Antibodies)-inducing transcription factors and significantly increased E-cadherin (show CDH1 Antibodies) expression. Concurrent downregulation of SPRY1 and SPRY2 (show SPRY2 Antibodies) also increased E-cadherin (show CDH1 Antibodies) and suppressed mesenchymal markers in colon cancer cells.
Spry1 plays a selective role in at least a subset of triple-negative breast cancer to promote the malignant phenotype via enhancing EGF (show EGF Antibodies)-mediated mesenchymal phenotype.
Suppression of SPRY1 by age-associated methylation inhibits the replenishment of the muscle stem cell pool.
Cosuppression of Sprouty and Sprouty-related negative regulators of FGF signalling in prostate cancer
There is an inverse correlation between the expression of Spry1 and growth, proliferation, invasion and migration of ovarian cancer cells.
A random population of LNCaP prostate cancer cells comprises a heterogeneous group of cells with different androgen-deprivation sensitivities and potential for invasiveness; expression levels of 2 genes known to be regulated by miR (show MLXIP Antibodies)-21, an androgen-regulated microRNA, SPRY1 and JAG1 (show JAG1 Antibodies) were lower in an androgen insensitive clone, than an androgen sensitive clone.
The Spry1 acts as a sensor of mitogenic activity that not only attenuates RTK signaling but also induces a cellular senescence response to avoid uncontrolled proliferation.
Spry1 and Spry4 (show SPRY4 Antibodies) have opposing roles in VSMC phenotypic modulation, and Spry1 maintains the VSMC differentiation phenotype in vitro in part through an Akt (show AKT1 Antibodies)/FoxO (show FOXO3 Antibodies)/myocardin (show MYOCD Antibodies) pathway.
Re-expression of SPRY1, a repressed target of BCL11B (show BCL11B Antibodies), limits the transformation capacity of Ewing sarcoma cells.
The results show that lnc-Spry1 could act as an early mediator of TGF-beta (show TGFB1 Antibodies) signaling and reveal different roles for a long noncoding RNA in modulating transcriptional and posttranscriptional gene expression.
modulation of stromal paracrine signaling and extracellular matrix remodeling by SPRY1 regulates mammary epithelial morphogenesis during postnatal development.
Here, we present a novel mouse model of pheochromocytoma consisting of double-heterozygous mice for Pten and Sprouty1 (Spry1), which leads to pheochromocytomas that appear at earlier onset and grow at a higher rate than those from Pten+/- mice.
Sprouty gain of function disrupts lens cellular processes and growth by restricting receptor tyrosine kinase (show ERBB3 Antibodies) signaling.
In vivo analysis of thyroid glands from Spry1 knockout mice reveals that Spry1 induces a senescence-associated secretory phenotype via activation of the NFkappaB pathway.
showed that hSpry1 overexpression prevents VEGF secretion
Spry1 and Spry2 (show SPRY2 Antibodies) coordination is required for normal development of the external genitalia in mice
conjunctival epithelial Spry1 and Spry2 (show SPRY2 Antibodies) redundantly promote eyelid closure.
Findings demonstrate that Pokemon (show ZBTB7A Antibodies) suppresses Sprouty1 expression through a miR (show MLXIP Antibodies)-21-mediated mechanism, affecting the growth and proliferation of liver cancer cells.
May function as an antagonist of fibroblast growth factor (FGF) pathways and may negatively modulate respiratory organogenesis.
protein sprouty homolog 1
, sprouty, Drosophila, homolog of, 1 (antagonist of FGF signaling)
, sprouty 1 protein
, sprouty homolog 1, antagonist of FGF signaling (Drosophila)
, sprouty homolog 1, antagonist of FGF signaling
, sprouty 1
, sprouty homolog 1a, antagonist of FGF signaling
, sprouty homolog 1b, antagonist of FGF signaling
, inhibitor of receptor tyrosine kinases